Evidence map›Paper›PMID 31604435›Full record

ArticleBMC veterinary research2019

Open field study on the efficacy of fluralaner topical solution for long-term control of flea bite allergy dermatitis in client owned cats in Ile-de-France region.

Amaury Briand, Noelle Cochet-Faivre, Pascal Prélaud, Rob Armstrong, Céline Hubinois

Open access · goldAbstract read
In one paragraph

Article in BMC veterinary research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Amaury BriandDepartment of Parasitology, Mycology, Dermatology, EA 7380 UPEC Dynamyc, Ecole nationale vétérinaire d'Alfort, F-94700, Maisons-Alfort, France. amaury.briand@gmail.com.ORCID http://orcid.org/0000-0002-3440-1270
Noelle Cochet-FaivreDepartment of Parasitology, Mycology, Dermatology, EA 7380 UPEC Dynamyc, Ecole nationale vétérinaire d'Alfort, F-94700, Maisons-Alfort, France.
Pascal PrélaudADVETIA Veterinary Hospital center, 9 Avenue Louis Breguet, 78140, Vélizy-Villacoublay, France.
Rob ArmstrongMerck Animal Health, 2 Giralda Farms, Madison, NJ, USA.
Céline HubinoisMSD Santé Animale, 7 Rue Olivier de Serres - Angers Technopole CS17144 -49 071, Beaucouze, France.
École Nationale Vétérinaire d'Alfort · FRDépartement Santé Animale · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFlea bite is considered to be the main cause of allergic dermatitis in cats. There is a need for treatments able to control clinical signs of allergic dermatitis associated with flea bite in cats. This was an open pre-treatment versus post-treatment clinical field study. All cats included in the study presented pruritus, skin lesions or other evidence compatible with flea infestation. Skin lesions were assessed (using SCORFAD) at days 0, 28, 56 and 84 whereas pruritus severity was assessed (using PVAS) at days 0, 15, 28, 56 and 84. On day 0, The fluralaner (280 mg/ml) product (Bravecto® spot-on for cats) was supplied in pipettes containing 0.4, 0.89 and 1.79 ml for cats of 1.2-2.8 kg, > 2.8-6.25 kg and > 6.25-12.5 kg body weight, respectively. The other animals living in the same household also received fluralaner. Based on cytological examination at day 0, oral amoxicillin and clavulanic acid was prescribed for 21 days if indicated. For cats presenting intense pruritus and discomfort at day 0, oral prednisolone at 0.5 mg/kg was prescribed for 3 days.

resultsDuring the study all cats, except for one (cat number 10), improved significantly. Post-treatment median SCORFAD scores at all evaluations were significantly different from the pre-treatment score on day 0 (P values < 0.002 for all three post treatment examination days) with a score reduction of 49% on day 28, 79% on day 56 and 87% on day 84. The PVAS score decreased significantly over the study period for all cats but one (cat number 10). Post-treatment median PVAS scores at all evaluations were significantly different from the pre-treatment PVAS score on day 0 (P value < 0.002 for all four post-treatment days) with a reduction of 46% on day 15, 67% on day 28, 82% on day 56 and 92% on day 84. No adverse reaction or other health issue was reported during the study.

conclusionsA single topical treatment with fluralaner results in a significant reduction of flea bite allergic dermatitis clinical signs in cats over the subsequent 12 weeks without any additional environmental treatment.

Indexed as

Administration, TopicalAmoxicillinAnimalsCat DiseasesCatsClavulanic AcidCtenocephalidesDermatitis, AtopicFemaleFlea InfestationsFranceInsecticidesIsoxazolesMalePrednisolonePruritusA1443 compoundAmoxicillinClavulanic AcidInsecticidesIsoxazolesPrednisoloneAllergic dermatitisCatClinical scoreEctoparasiteFleasFluralaner

Identifiers

PMID31604435
PMCPMC6788036
OpenAlexW2980108356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.